<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144782">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02128685</url>
  </required_header>
  <id_info>
    <org_study_id>UW 13-292</org_study_id>
    <nct_id>NCT02128685</nct_id>
  </id_info>
  <brief_title>Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Threatened Miscarriage</brief_title>
  <official_title>A Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Women With Threatened Miscarriage in the First Trimester</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <authority>Hong Kong: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether the dydrogesterone therapy is associated with
      reduction in miscarriage in women with first trimester threatened miscarriage. The
      hypothesis is that the dydrogesterone therapy will significantly reduce the risk of
      miscarriage in women with threatened miscarriage.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The chance of miscarriage before 20 weeks of gestation</measure>
    <time_frame>20 weeks of gestation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidences of antepartum hemorrhage, placenta previa, pregnancy-induced hypertension, intrauterine death, congenital abnormality, preterm labour (28-36 weeks), low birth weight at term (&lt;2500g) and full term delivery</measure>
    <time_frame>Antenatal till delivery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>First Trimester Threatened Miscarriage Treatment</condition>
  <condition>Dydrogesterone Therapy</condition>
  <arm_group>
    <arm_group_label>Dydrogesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone</intervention_name>
    <arm_group_label>Dydrogesterone</arm_group_label>
    <other_name>Duphaston</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of women from 18-40 years at the time of recruitment (not beyond 40th birthday)

          -  Spontaneous conception

          -  Absence of systemic illness or fever

          -  No history of passage of conception material

          -  Gestation less than 12 completed weeks

          -  A singleton intrauterine fetus with fetal heart pulsation confirmed on pelvic
             scanning

        Exclusion Criteria:

          -  Age of women &gt;40 years at the time of recruitment

          -  Assisted conception including intrauterine insemination and in vitro fertilization
             treatment

          -  History of recurrent miscarriage

          -  History of chromosomal abnormalities

          -  History of positive anti-phospholipid antibody

          -  Presence of congenital uterine abnormality on pelvic scanning

          -  Heavy vaginal bleeding requiring surgical intervention

          -  Severe abdominal pain

          -  Twin pregnancy on scanning

          -  Absence of cardiac pulsation in a fetal pole on transvaginal scanning

          -  Use of progesterone treatment for threatened miscarriage before recruitment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Man Ka Diana Chan, MBBS(HK)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynaecology, Queen Mary Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Man Ka Diana Chan, MBBS(HK)</last_name>
    <phone>22554517</phone>
    <email>dcmanka@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics &amp; Gynaecology, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Man Ka Diana Chan, MBBS(HK)</last_name>
      <phone>22554517</phone>
      <email>dcmanka@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>April 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CHAN MAN KA DIANA</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>Threatened miscarriage</keyword>
  <keyword>Dydrogesterone</keyword>
  <keyword>Randomized controlled trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Threatened</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
